WO2004013634A3 - Polypeptide de reparation d'adn endommage et leur utilisation - Google Patents

Polypeptide de reparation d'adn endommage et leur utilisation Download PDF

Info

Publication number
WO2004013634A3
WO2004013634A3 PCT/GB2003/003004 GB0303004W WO2004013634A3 WO 2004013634 A3 WO2004013634 A3 WO 2004013634A3 GB 0303004 W GB0303004 W GB 0303004W WO 2004013634 A3 WO2004013634 A3 WO 2004013634A3
Authority
WO
WIPO (PCT)
Prior art keywords
dna damage
polypeptide
damage repair
repair polypeptide
mdc1
Prior art date
Application number
PCT/GB2003/003004
Other languages
English (en)
Other versions
WO2004013634A2 (fr
Inventor
Stephen Jackson
Michal Goldberg
Manuel Stucki
Original Assignee
Kudos Pharm Ltd
Stephen Jackson
Michal Goldberg
Manuel Stucki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kudos Pharm Ltd, Stephen Jackson, Michal Goldberg, Manuel Stucki filed Critical Kudos Pharm Ltd
Priority to AU2003281785A priority Critical patent/AU2003281785A1/en
Publication of WO2004013634A2 publication Critical patent/WO2004013634A2/fr
Publication of WO2004013634A3 publication Critical patent/WO2004013634A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne l'identification d'un composant de polypeptides de la voie de signalisation de l'endommagement de l'ADN dépendant de l'ATM, qui interagit avec d'autres facteurs de réaction à l'endommagement de l'ADN, notamment le complexe MRE11 et 53BP1. La modulation des interactions dudit polypeptide appelé MDC1 (médiateur de la protéine 1 de point de contrôle de l'endommagement de l'ADN) permet des applications thérapeutiques, par exemple dans le traitement du cancer ou des infections virales.
PCT/GB2003/003004 2002-08-01 2003-07-10 Polypeptide de reparation d'adn endommage et leur utilisation WO2004013634A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003281785A AU2003281785A1 (en) 2002-08-01 2003-07-10 Dna damage repair polypeptide and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40087302P 2002-08-01 2002-08-01
US60/400,873 2002-08-01

Publications (2)

Publication Number Publication Date
WO2004013634A2 WO2004013634A2 (fr) 2004-02-12
WO2004013634A3 true WO2004013634A3 (fr) 2004-04-15

Family

ID=31495894

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/003004 WO2004013634A2 (fr) 2002-08-01 2003-07-10 Polypeptide de reparation d'adn endommage et leur utilisation

Country Status (2)

Country Link
AU (1) AU2003281785A1 (fr)
WO (1) WO2004013634A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2466310A1 (fr) 2010-12-17 2012-06-20 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Supports et procédés de détection de cassures à double brin
US10197578B2 (en) 2014-02-17 2019-02-05 Universite Claude Bernard Lyon 1 Predictive method of characterizing the radiosensitivity and tissular reaction of a patient to therapeutic ionizing radiation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003001225A1 (fr) * 2001-06-06 2003-01-03 Brown University Research Foundation Microscope magnetique a balayage muni d'un capteur magnetique ameliore
US20030027167A1 (en) * 2001-08-01 2003-02-06 Rigel Pharmaceuticals, Inc. MRE11: modulation of cellular proliferation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003001225A1 (fr) * 2001-06-06 2003-01-03 Brown University Research Foundation Microscope magnetique a balayage muni d'un capteur magnetique ameliore
US20030027167A1 (en) * 2001-08-01 2003-02-06 Rigel Pharmaceuticals, Inc. MRE11: modulation of cellular proliferation

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
GOLDBERG MICHAL ET AL: "MDC1 is required for the intra-S-phase DNA damage checkpoint.", NATURE. ENGLAND 27 FEB 2003, vol. 421, no. 6926, 27 February 2003 (2003-02-27), pages 952 - 956, XP002267898, ISSN: 0028-0836 *
LOU ZHENKUN ET AL: "MDC1 is coupled to activated CHK2 in mammalian DNA damage response pathways.", NATURE. ENGLAND 27 FEB 2003, vol. 421, no. 6926, 27 February 2003 (2003-02-27), pages 957 - 961, XP002267897, ISSN: 0028-0836 *
LOU ZHENKUN ET AL: "Mediator of DNA damage checkpoint protein 1 regulates BRCA1 localization and phosphorylation in DNA damage checkpoint control.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 18 APR 2003, vol. 278, no. 16, 18 April 2003 (2003-04-18), pages 13599 - 13602, XP002267893, ISSN: 0021-9258 *
PENG AIMIN ET AL: "NFBD1, like 53BP1, is an early and redundant transducer mediating Chk2 phosphorylation in response to DNA damage.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 14 MAR 2003, vol. 278, no. 11, 14 March 2003 (2003-03-14), pages 8873 - 8876, XP002267894, ISSN: 0021-9258 *
SHANG YONG LEI ET AL: "NFBD1, a novel nuclear protein with signature motifs of FHA and BRCT, and an internal 41-amino acid repeat sequence, is an early participant in DNA damage response.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 21 FEB 2003, vol. 278, no. 8, 21 February 2003 (2003-02-21), pages 6323 - 6329, XP002267899, ISSN: 0021-9258 *
STEWART GRANT S ET AL: "MDC1 is a mediator of the mammalian DNA damage checkpoint.", NATURE. ENGLAND 27 FEB 2003, vol. 421, no. 6926, 27 February 2003 (2003-02-27), pages 961 - 966, XP002267896, ISSN: 0028-0836 *
XU XINGZHI ET AL: "NFBD1/KIAA0170 is a chromatin-associated protein involved in DNA damage signaling pathways.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 7 MAR 2003, vol. 278, no. 10, 7 March 2003 (2003-03-07), pages 8795 - 8803, XP002267895, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
AU2003281785A8 (en) 2004-02-23
AU2003281785A1 (en) 2004-02-23
WO2004013634A2 (fr) 2004-02-12

Similar Documents

Publication Publication Date Title
WO2003014303A3 (fr) Interactions moleculaires dans les cellules
WO2001019981A3 (fr) Genomique fonctionnelle utilisant des proteines a doigts de zinc
ATE509120T1 (de) Fusionsproteine zur detektion von analyten
EP2322552A3 (fr) Anticorps se liant à IL-1 beta et fragments de ceux-ci
ATE444967T1 (de) Spezifische bindungsmittel von human angiopoietin-2
EP1674477A3 (fr) Polypeptides de liaison pour la protéine stimulatrice des lymphocytes B (BLyS)
AU2002217010A1 (en) Peptides, the production and use thereof for binding immunoglobulins
WO2004092210A3 (fr) Molecule
WO2005047459A3 (fr) Acides nucleiques du sars, proteines, anticorps et utilisations associees
DE60233532D1 (de) An proteinphosphatase 2a bindende synthetische ode anwendungen
DE60138715D1 (de) Tnf-rezeptor-ähnliche moleküle und deren anwendungen
WO2004029072A3 (fr) Molecules interagissant avec prpsc et utilisations associees
WO2003087138A3 (fr) Procedes d'identification de facteurs polypeptidiques ayant une interaction avec l'arn
DK1537140T3 (da) Nukleinsyre og tilsvarende protein betegnet 161P2F10B, der er anvendelige i behandling og detektering af cancer
WO2003016551A3 (fr) Proteine de liaison a l'acide salicylique codant des acides nucleiques, proteine de liaison a l'acide salicylique 2 (sabp2) et methodes d'utilisation associees
DK1372719T3 (da) Nukleinsyre og tilsvarende protein betegnet 125P5C8, der er anvendelig i behandling og påvisning af cancer
WO2004013634A3 (fr) Polypeptide de reparation d'adn endommage et leur utilisation
PL374550A1 (en) Il-17 like molecules and uses thereof
WO2002062964A3 (fr) Variants d'amine oxydase ap1
ATE528392T1 (de) Neues protein und dessen dns
AU2002258630A1 (en) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
DE60120187D1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
WO2002079222A3 (fr) Proteines de fusion pour le traitement specifique du cancer et de maladies auto-immunes
WO2002102982A3 (fr) Compositions a base d'hoxd3 et procedes pour ameliorer la cicatrisation
DK2186898T3 (da) Blomstrings-induktion

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP